Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXCAN Pharma(AXCA)..A GUT FEELING! -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15)	8/19/2000 11:08:02 PM
From: Arthur Radley	Respond to of 46

Peter, I must admit that I got a chuckle out of the Pat Buchanan comment.(:>) The gall of that man! Can't disagree with your points on Urso for gallstone treatment. However, it is the other potential areas that I find interesting. From the annual report it appears that they have trials going on for the following: 1) non-alcoholic steatohepatis 2) recurrence of colorectal polyps(this 600 patient trial should have results released within weeks) 3) primary sclerosing cholangitis 4) primary hypercholesterolemia(results due by end of year) It appears that from the biliary cirrhosis trials they noted that patients had a decrease of total serum cholesterol levels. It is this potential that has my attention..being I'm a Zocor user myself.

To: Biomaven who wrote (15)	9/1/2000 9:43:42 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 46

More good news for AXCA. AXCAN PHARMA INC - Added to TSE 300 Composite Index Toronto, Ontario, Sep. 01, 2000 (Market News Publishing via COMTEX) -- Axcan Pharma Inc. ("Axcan") is pleased to announce that the Company has been added today to the TSE 300 Composite Index. "This addition to the TSE 300 is a tremendous recognition of Axcan's progress over the past few years," commented Leon F. Gosselin, President and CEO. "This places us among Canada's leading companies and will definitely increase investor awareness," he added. The TSE 300 Composite Index was created in 1977 by the Toronto Stock Exchange and is maintained by Standard & Poor's. Comprised of 300 of Canada's larger public companies traded on the Toronto Stock Exchange, the TSE 300 is widely regarded as a barometer of Canadian equity markets. Inclusion in the TSE 300 is made only after review by Standard & Poor's and in accordance with strict criteria. Axcan is a leading North American pharmaceutical company in the field of gastroenterology. Axcan is the only Canadian pharmaceutical company with its own US sales and marketing organization and its common shares are listed on the Toronto Stock Exchange under the symbol 'AXP' and on the NASDAQ National Market under the symbol "AXCA". "This press release contains forward-looking statements, which reflect the Corporation's